Molecular	0	9	O
characterization	10	26	O
of	27	29	O
angiogenic	30	40	O
properties	41	51	O
of	52	54	O
human	55	60	B-Organism
oral	61	65	B-Cell
squamous	66	74	I-Cell
cell	75	79	I-Cell
carcinoma	80	89	I-Cell
cells	90	95	I-Cell
.	95	96	O

Little	98	104	O
is	105	107	O
known	108	113	O
about	114	119	O
the	120	123	O
specificity	124	135	O
of	136	138	O
angiogenic	139	149	O
properties	150	160	O
of	161	163	O
oral	164	168	B-Cell
cancer	169	175	I-Cell
cells	176	181	I-Cell
and	182	185	O
the	186	189	O
possible	190	198	O
mechanisms	199	209	O
.	209	210	O

Stimulatory	211	222	O
effects	223	230	O
on	231	233	O
proliferation	234	247	O
and	248	251	O
migration	252	261	O
of	262	264	O
human	265	270	B-Cell
umbilical	271	280	I-Cell
vein	281	285	I-Cell
endothelial	286	297	I-Cell
cells	298	303	I-Cell
(	304	305	O
HUVEC	305	310	B-Cell
)	310	311	O
characterized	312	325	O
the	326	329	O
angiogenic	330	340	O
properties	341	351	O
of	352	354	O
oral	355	359	B-Cell
cancer	360	366	I-Cell
cells	367	372	I-Cell
but	373	376	O
not	377	380	O
normal	381	387	B-Cell
oral	388	392	I-Cell
keratinocytes	393	406	I-Cell
(	407	408	O
NOK	408	411	B-Cell
)	411	412	O
.	412	413	O

ELISA	414	419	O
found	420	425	O
the	426	429	O
presence	430	438	O
of	439	441	O
vascular	442	450	B-Gene_or_gene_product
endothelial	451	462	I-Gene_or_gene_product
growth	463	469	I-Gene_or_gene_product
factors	470	477	I-Gene_or_gene_product
(	478	479	O
VEGF	479	483	B-Gene_or_gene_product
)	483	484	O
both	485	489	O
in	490	492	O
the	493	496	O
tested	497	503	O
oral	504	508	B-Cell
cancer	509	515	I-Cell
cells	516	521	I-Cell
and	522	525	O
NOK	526	529	B-Cell
.	529	530	O

Attenuation	531	542	O
of	543	545	O
the	546	549	O
proangiogenic	550	563	O
effects	564	571	O
by	572	574	O
neutralizing	575	587	O
VEGF	588	592	B-Gene_or_gene_product
antibodies	593	603	O
suggests	604	612	O
VEGF	613	617	B-Gene_or_gene_product
play	618	622	O
a	623	624	O
key	625	628	O
role	629	633	O
in	634	636	O
the	637	640	O
acquisition	641	652	O
of	653	655	O
the	656	659	O
angiogenic	660	670	O
phenotype	671	680	O
in	681	683	O
oral	684	688	B-Cell
cancer	689	695	I-Cell
cells	696	701	I-Cell
.	701	702	O

Western	703	710	O
blotting	711	719	O
of	720	722	O
p53	723	726	B-Gene_or_gene_product
and	727	730	O
murine	731	737	B-Gene_or_gene_product
double	738	744	I-Gene_or_gene_product
mutant	745	751	I-Gene_or_gene_product
2	752	753	I-Gene_or_gene_product
(	754	755	O
Mdm2	755	759	B-Gene_or_gene_product
)	759	760	O
together	761	769	O
with	770	774	O
p53	775	778	B-Gene_or_gene_product
DNA	779	782	O
sequencing	783	793	O
analysis	794	802	O
indicate	803	811	O
that	812	816	O
p53	817	820	B-Gene_or_gene_product
function	821	829	O
loss	830	834	O
by	835	837	O
mutation	838	846	O
or	847	849	O
overexpression	850	864	O
of	865	867	O
Mdm2	868	872	B-Gene_or_gene_product
occurred	873	881	O
in	882	884	O
all	885	888	O
tested	889	895	O
oral	896	900	B-Cell
cancer	901	907	I-Cell
cells	908	913	I-Cell
regardless	914	924	O
of	925	927	O
their	928	933	O
etiology	934	942	O
.	942	943	O

In	944	946	O
summary	947	954	O
,	954	955	O
the	956	959	O
angiogenic	960	970	O
property	971	979	O
of	980	982	O
oral	983	987	B-Cell
cancer	988	994	I-Cell
cells	995	1000	I-Cell
is	1001	1003	O
mediated	1004	1012	O
by	1013	1015	O
many	1016	1020	O
factors	1021	1028	O
in	1029	1031	O
addition	1032	1040	O
to	1041	1043	O
VEGF	1044	1048	B-Gene_or_gene_product
and	1049	1052	O
the	1053	1056	O
functional	1057	1067	O
status	1068	1074	O
of	1075	1077	O
p53	1078	1081	B-Gene_or_gene_product
.	1081	1082	O

